Withdrawing Amantadine in Dyskinetic Patients with Parkinson Disease
Neurol 82:300-307, Ory-Magne, F.,et al, 2014
Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
Clinicopath Conf, Dopamine-Responsive-Dystonia Caused by a Mutation in the GCH1 Gene
NEJM 355:831-839, Case 26-2006, 2006
A Five-Year Study of the Incidence of Dyskinesia in Patients With Early Parkinson's Disease who were Treated with Ropinirole or Levodopa
NEJM 342:1484-1491, Rascol,O.,et al, 2000
Subcotical Arteriosclerotic Encephalopathy (Binswangers Disease)
, Ghika,J. &Bogousslavsky, J., 1998
Low-Dose Clozapine Improves Dyskinesias in Parkinson's Disease
Neurol 48:658-662, Durif,F.,et al, 1997
Managing the Late Complications of Parkinson's Disease
Neurol 49:549-557, Waters,C.H., 1997
Neuroleptic Drug Exposure and Treatment of Parkinsonism in the Elderly:A Case-Control Study
Am J Med 99:48-54, Avorn,J.,et al, 1995
Increased Incidence of Levodopa Therapy Following Metoclopramide Use
JAMA 274:1780-1782, Avorn,J.,et al, 1995
Parkinsonism Induced by Solvent Abuse
Ann NEurol 35:616-618, Uitti,R.J.,et al, 1994
Dopa-Responsive Dystonia:Long-Term Treatment Response and Prognosis
Neurol 41:174-181, Nygaard,T.G.,et al, 1991
Early Development of Levodopa-Induced Dyskinesias and Response Fluctuations in Young-Onset Parkinson's Disease
Neurol 41:202-205, Kostic,V., 1991
Levodopa-Induced Dyskinesia:Review, Observations, and Speculations
Neurol 40:340-345, Nutt,J.G., 1990
Dopa Responsive Dystonia:A Treatable Condition Misdiagnosed as Cerebral Palsy
BMJ 298:1019-1020, Boyd,K.&Patterson,V., 1989
Chronic Manganese Intoxication
Arch Neurol 46:1104-1106, Huang,C.C.,et al, 1989
Neuroleptic-Induced Parkinson's Syndrome:Clinical Features and Results of Treatment with Levodopa
JNNP 51:850-854, Hardie,R.J.&Lees,A.J., 1988
Drug-induced Asterixis in Parkinson Disease
Neurol 32:553-555, Glantz,R.,et al, 1982
Onset & End-of-dose Levodopa-induced Dyskinesias
Arch Neurol 35:261, Lhermitte,F.,et al, 1978
Catecholamines & Neurologic Diseases
NEJM 293:274, Moskowitz,M.A.,et al, 1975
Implications of Amphetamine-Induced Stereotyped Behavior as a Model for Tardive Dyskinesias
Arch Gen Psychiat 27:502-507, Rubovits,R.,et al, 1972
Drug-Induced Movement Disorders
Postgrad Med 180, 1971, Sept., North,R., 1971
A Young Woman With Hypertonia, Severe Scoliosis, and Encephalopathy
JAMA Neurol 81:83-84, Hua,L.,et al, 2024
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Progressive Supranuclear Palsy: A Current Review
The Neurologist 14:79-88, Lubarsky,M. &Juncos,J.L., 2008
Tolcapone for Parkinson's Disease
The Medical Letter 40:60-61, , 1998
Long-Term Follow-Up of Levodopa Responsiveness in Generalized Dystonia
Arch Neurol 55:1320-1323, Dewey,R.B.,et al, 1998
Levodopa-Nonresponsive Lewy Body Parkinsonism:Clinicopathologic Study of Two Cases
Neurol 42:1323-1327, Mark,M.H.,et al, 1992
Huntington's Chorea-Deficiency of Y-Aminobutynic Acid in Brain
NEJM 288:337, 1973, 289:104, 1973, 292:10295., Perry,T.,et al, 1975
Progressive Supranuclear Palsy-Case Study
NEJM 293:346, Richardson,E.P., 1975
Involuntary Groaning Induced by Levodopa Therapy in a Patient With Progressive Supranuclear Palsy
JAMA Neurol 77:1569, Park, J.E., 2020
A 56-year-old Man with Cognitive Impairment and Difficulty Tying his Necktie
Neurol 85:e116-e122, Baker, J.M.,et al, 2015
Disturbances of Cerebrospinal Fluid, Including Hydrocephalus, Pseudotumor Cerebri, and Low-Pressure Syndromes, Parkinsonism and Midbrain Syndromes with Hydrocephalus and Shunting
Adams & Victors Principles of Neurology, Chp 30, pg 627, Ropper, A.H.,et al, 2014
Neurostimulation for Parkinsons Disease with Early Motor Complications
NEJM 368:610-622, Rau, W.,et al, 2013
Parkin Disease
JAMA Neurol 70:571-579, Doherty, K.,et al, 2013
Othello Syndrome in Parkinson Disease Patients Without Dementia
The Neurologist 15:34-36, Cannas,A.,et al, 2009
Long-Term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease
Arch Neurol 66:563-570, Parkinson Sutdy Group CALM Cohort Investigators, 2009
Fourteen-Year Final Report of the Randomized PDRG-UK Trial Comparing Three Treatments in PD
Neurol 71:474-480.470, Katzenschlager,R.,et al., 2008
Functional Abnormalities Underlying Pathological Gambling in Parkinson Disease
Arch Neurol 65:1604-1611, Cilia,R.,et al, 2008
Treatment Options in the Modern Management of Parkinson Disease
Arch Neurol 64:1083-1088, Schapira,A.H.V., 2007
Vascular Parkinsonism and Dementia in a CADASIL Case with Intact Nigrostriatal Dopaminergic System
Akt Neurol 33: Suppl, Wegner,F.,et al, 2006
Dopamine-Responsive Dystonia
eMedicine (Apr), Nikhar,N.K., 2006
"Levodopa Phobia": A New Iatrogenic Cause of Disability in Parkinson Disease
Neurol 64:923-924, Kurlan, R., 2005
Effect of Levodopa Treatment for Parkinsonism in Welders
Neurol 62:730-733, Koller,W.C.,et al, 2004
Levodopa and the Progression of Parkinson's Disease
NEJM 351:2498-2508, The Parkinson Study Group, 2004
Restless Legs Syndrome
NEJM 348:2103-2109, Earley,C.J., 2003
Awakenings From Persistent Vegetative State: Report of Three Cases With Parkinsonism and Brain Stem Lesions on MRI
JNNP 74:1571-1573, Matsuda,W.,et al, 2003
Treatments of Parkinson Disease
Arch Neurol 60:1680-1684, Shults,C.W., 2003
Levodopa Addiction in Non-Parkinsonian Patients
Neurol 61:1451, Steiner,I. &Wirguin,I., 2003
Subthalamic DBS Replaces Levodopa in Parkinson's Disease
Neurol 58:396-401, Vingerhoets,F.J.G.,et al, 2002